Continuous Manufacturing On Horizon As Competitive Edge In OTC Space
This article was originally published in The Tan Sheet
Executive Summary
While OTC firms’ slimmer profit margins make equipment changes or other capital investments more difficult for them than for Rx firms, continuous manufacturing will be worth the investment, says CDER Director Janet Woodcock. “We’re going to see a lot of these out there,” she says.